SynAct Begins Phase II Study on AP1189 for Membranous Nephropathy

This morning, SynAct Pharma AB announced in a press release that they began a Phase II clinical trial to determine the efficacy and safety of AP1189 on treating patients with idiopathic membranous nephropathy (iMN) and nephrotic syndrome (NS).

Membranous Nephropathy

Membranous nephropathy (MN) is a kidney disorder in which glomeruli, or small blood vessels, become inflamed and thickened. Normally, glomeruli help filter waste from the blood. But when they are damaged, proteins leak into the urine, causing symptoms of nephrotic syndrome.

Idiopathic means that a condition occurred spontaneously or from an unknown cause. So idiopathic membranous nephropathy refers to the fact that doctors aren’t really sure what causes it. However, some potential causes include autoimmune disorders, infections, medication usage, cancer, or other kidney diseases.

Symptoms of membranous nephropathy include:

  • Fatigue
  • Foamy urine
  • High cholesterol
  • Weight gain
  • Swelling, particularly in the legs and ankles
  • Proteinuria, or increased protein in the urine
  • Increased levels of fat in the blood
  • Needing to urinate more

Learn more about membranous nephropathy.

Nephrotic Syndrome

Idiopathic membranous nephropathy is one of the leading causes of nephrotic syndrome in adult patients. According to the American Kidney Fund, nephrotic syndrome:

is a group of symptoms that show your kidneys are not working as well as they should. These symptoms include too much protein in your urine, not enough protein in your blood, too much fat or cholesterol in your blood, and swelling.

Nephrotic syndrome is more common in males than females. If it occurs in children, symptoms usually develop between the ages of 2 and 6.

AP1189 Study

The Phase II study for AP1189 will be double-blind, multi-center, and placebo-controlled. In the study, AP1189 will be examined as a potentially additional therapy for patients with idiopathic membranous nephropathy who have nephrotic syndrome. Currently, first treatments for patients with iMN are Angiotensin II receptor blockers or Angiotensin-converting-enzyme inhibitors. In this case, patients will receive 1 dose daily (100mg AP1189) OR a placebo for a 1 month period. Researchers seek to understand how this treatment impacts proteinuria, or protein levels in the urine.

Jessica Lynn

Jessica Lynn

Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email